Efficacy and Safety of Zanubrutinib in Japanese Patients With B-Cell Malignancies

<u>Kohmei Kubo</u>,¹ Masahiro Takeuchi,² Takayuki Ishikawa,³ Kazuyuki Shimada,⁴ Takeshi Kondo,⁵ Katsuya Fujimoto,⁶ Tomoaki Fujisaki,⁷ Shingo Kurahashi,⁸ Koji Nagafuji,⁹ Rika Sakai,¹⁰ Tomonori Nakazato,¹¹ Kazutaka Sunami,¹² Senji Kasahara,¹³ Haiyi Guo,¹⁴ Motohisa Takai,¹⁴ Jinhua Zhong,¹⁴ Koji Izutsu¹⁵

¹Aomori Prefectural Central Hospital, Aomori, Japan; ²Chiba-Ken Cancer Center, Chiba, Japan; ³Kobe City Medical Center General Hospital, Kobe, Japan; ⁴Nagoya University Hospital, Nagoya, Japan; ⁵Aiiku Hospital, Sapporo, Japan; ⁶National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; ⁷Matsuyama Red Cross Hospital, Matsuyama, Japan; ⁸Toyohashi Municipal Hospital, Toyohashi, Japan; ⁹Kurume University Hospital, Kurume, Japan; ¹⁰Kanagawa Cancer Center, Yokohama, Japan; ¹¹Yokohama Municipal Citizen's Hospital, Yokohama, Japan; ¹²National Hospital Organization Okayama Medical Center, Okayama, Japan; ¹³Gifu Municipal Hospital, Gifu, Japan; ¹⁴BeiGene (Shanghai) Co, Ltd, Shanghai, China, and BeiGene USA, Inc, San Mateo, CA, USA; ¹⁵National Cancer Center Hospital, Tokyo, Japan

Presented at: 85th Annual Meeting of the Japanese Society of Hematology; October 13-15, 2023; Tokyo, Japan. Correspondence: Kohmei Kubo; komei.kubo@nifty.com

Abstract 30055

COI disclosure

Kohmei Kubo, Masahiro Takeuchi, Takayuki Ishikawa, Kazuyuki Shimada, Takeshi Kondo, Katsuya Fujimoto, Tomoaki Fujisaki, Shingo Kurahashi, Koji Nagafuji, Rika Sakai, Tomonori Nakazato, Kazutaka Sunami, Senji Kasahara, Haiyi Guo, Motohisa Takai, Jinhua Zhong, Koji Izutsu

Author(s) have the following COI to disclose.

KF: Research funding from Parexel International Co, Ltd, Insight Biosciences Japan, LLC. KSu: Honoraria from Celgene, Bristol Myers Squibb, Takeda Pharmaceutical, Sanofi; research funding from Ono Pharmaceutical, MSD, Celgene, AbbVie G.K., Takeda Pharmaceutical, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Alexion Pharma, GSK, Otsuka Pharmaceutical, Novartis Pharma, Astellas, Amgen, Janssen Pharma, Chugai Pharmaceutical, Kyowa Kirin, Pfizer. SKa: Honoraria from Daiichi Sankyo; research funding from Novartis Pharma, Astellas Pharma, Daiichi Sankyo.
HG: Employment, stock options, travel fees, gifts, and other from BeiGene. MTaka, JZ: Employment and stock options from BeiGene. KI: Honoraria from Ono Pharmaceutical, Janssen; research funding from AstraZeneca, AbbVie, Incyte, Bristol Myers Squibb, Novartis, Janssen, Yakult, Daiichi Sankyo, Chugai, BeiGene, Genmab.

This study has been approved by the local IRB.

Background

- Zanubrutinib is a potent, selective, irreversible, next-generation BTK inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition and associated AEs¹
- Zanubrutinib is approved globally for the treatment of B-cell malignancies in adults²⁻⁴
- BGB-3111-111 (NCT04172246) is an ongoing, multicenter, open-label phase 1/2 study to assess the safety and efficacy of zanubrutinib in Japanese patients with mature B-cell malignancies
- An IRC-based efficacy assessment is key to confirm the reliability of the study and support regulatory approval from agencies

Here, we present the IRC-assessed efficacy of zanubrutinib in Japanese patients and report concordance with the investigator-based assessment in the BGB-3111-111 study from the 2022 DCO

AE, adverse event; BTK, Bruton tyrosine kinase; DCO, data cut-off; IRC, independent review committee.
1. Guo Y, et al. *J Med Chem*. 2019;62(17):7923-7940; 2. Brukinsa. Package insert. BeiGene USA, Inc; 2023;
3. Brukinsa. Product monograph. Beigene Switzerland GmbH; 2021; 4. Gale RP. *Chin Med J (Engl)*. 2022;135(8):883-886.


Study design

Key eligibility criteria

• Japanese


- •Age ≥20 years
- •ECOG PS of 0-2
- Confirmed diagnosis of mature B-cell neoplasms (CLL/SLL, MCL, FL, MZL, or WM)
- •Measurable disease^a
- No prior systemic chemotherapy or radiation therapy within 2 weeks prior to first dose of zanubrutinib

• No prior alloSCT or therapy with B-cell receptor inhibitor or BCL2 inhibitor



alloSCT, allogeneic stem cell transplant; BCL2, B-cell lymphoma 2; BID, twice daily; DLT, dose-limiting toxicity; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; INV, investigator; IRC, independent review committee; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; QD, once daily; R/R, relapsed or refractory; SMC, safety monitoring committee; TEAE, treatment-emergent adverse event; TN, treatment naive; TTR, time to response; WM, Waldenström macroglobulinemia.

Patient disposition



Data cutoff date: 10 May 2022

CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma; R/R, relapsed or refractory; TN, treatment naive; WM, Waldenström macroglobulinemia.


Baseline characteristics

	CLL/SLL (n=17)			/M =21)	R/R MCL	Total	
Characteristics	TN (n=14)	R/R (n=3)	TN (n=13)	R/R (n=8)	(n=12)	(N=53)	
Age, median (range), years	67.5 (38-77)	76.0 (72-77)	71.0 (37-83)	67.5 (61-78)	74.5 (58-84)	71.0 (37-84)	
<65 years, n (%)	6 (42.9)	0	3 (23.1)	2 (25.0)	1 (8.3)	13 (24.5)	
≥65 years, n (%)	8 (57.1)	3 (100)	10 (76.9)	6 (75.0)	11 (91.7)	40 (75.5)	
Sex, n (%)							
Male	10 (71.4)	2 (66.7)	6 (46.2)	5 (62.5)	10 (83.3)	36 (67.9)	
Female	4 (28.6)	1 (33.3)	7 (53.8)	3 (37.5)	2 (16.7)	17 (32.1)	
ECOG PS, n (%)							
0	12 (85.7)	3 (100)	10 (76.9)	5 (62.5)	9 (75.0)	42 (79.2)	
1	2 (14.3)	0	3 (23.1)	3 (37.5)	3 (25.0)	11 (20.8)	
No. of prior lines of therapy in patients with R/R disease, median (range)	_	2.0 (1-2)	_	3.5 (1-8)	1.0 (1-2)	2.0 (1-8)	

CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; 6 MCL, mantle cell lymphoma; R/R, relapsed or refractory; TN, treatment naive; WM, Waldenström macroglobulinemia.

Patients with CLL/SLL had an ORR of >90%






 The proportion of patients with CLL/SLL who had a consistent assessment of overall response by IRC and INV was >90%

CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; INV, investigator; IRC, independent review committee; ORR, overall response rate; PR, partial response; PR-L, partial response with lymphocytosis; R/R, relapsed or refractory; SD, stable disease; TN, treatment naive.

^a Estimated using the Clopper-Pearson method.

Patients with WM had an ORR of >90%



 The proportion of patients with WM and R/R MCL who had a consistent assessment of overall response by IRC and INV was >90%


CR, complete response; INV, investigator; IRC, independent review committee; MCL, mantle cell lymphoma; MR, minor response;

NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; R/R, relapsed or refractory;

SD, stable disease; TN, treatment naive; VGPR, very good partial response; WM, Waldenström macroglobulinemia.


^a Estimated using the Clopper-Pearson method.

50% PFS was not reached in the CLL/SLL group



CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; INV, investigator; IRC, independent review committee; PFS, progression-free survival; R/R, relapsed or refractory; TN, treatment naive.

50% PFS was not reached in the WM or MCL groups



MCL, mantle cell lymphoma; INV, investigator; IRC, independent review committee; PFS, progression-free survival; R/R, relapsed or refractory; TN, treatment naive; WM, Waldenström macroglobulinemia.

Safety results were similar to previously published data¹⁻⁴

Most Common TEAEs (Incidence ≥10% of Total Patients)^a

	CLL/SLL (n=19)		WM (n=21)		R/R MCL (n=12)		Total (N=55)	
n (%)	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
≥1 TEAE	18 (94.7)	8 (42.1)	20 (95.2)	8 (38.1)	12 (100)	8 (66.7)	53 (96.4)	26 (47.3)
Platelet count decreased	3 (15.8)	3 (15.8)	4 (19.0)	2 (9.5)	2 (16.7)	0	10 (18.2)	5 (9.1)
Pyrexia	3 (15.8)	0	3 (14.3)	0	3 (25.0)	0	10 (18.2)	0
COVID-19	5 (26.3)	0	2 (9.5)	0	1 (8.3)	1 (8.3)	8 (14.5)	1 (1.8)
Neutrophil count decreased	3 (15.8)	3 (15.8)	3 (14.3)	3 (14.3)	1 (8.3)	0	7 (12.7)	6 (10.9)
Anemia	4 (21.1)	0	2 (9.5)	1 (4.8)	0	0	6 (10.9)	1 (1.8)
Arthralgia	0	0	5 (23.8)	0	1 (8.3)	0	6 (10.9)	0
Back pain	1 (5.3)	0	2 (9.5)	0	3 (25.0)	0	6 (10.9)	0
Constipation	4 (21.1)	0	1 (4.8)	0	0	0	6 (10.9)	0
Nasopharyngitis	2 (10.5)	0	4 (19.0)	0	0	0	6 (10.9)	0
Purpura	2 (10.5)	0	4 (19.0)	0	0	0	6 (10.9)	0

^a Median study follow-up time of 26.7 months (Data cutoff date: 10 May 2023)

CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma; R/R, relapsed or refractory;

TEAE, treatment-emergent adverse event; WM, Waldenström macroglobulinemia.

1. Tam CS, et al. Lancet Oncol. 2022;23(8):1031-1043; 2. Brown JR. N Engl J Med. 2023;388(4):319-332;

3. Tam CS, et al. Blood. 2020;136(18):2038-2050; 4. Dimopoulos MA, et al. J Clin Oncol. 2023; JCO2202830.

Rates of atrial fibrillation/flutter were low and similar to results from global studies¹⁻⁴

TEAEs of Special Interest^a

n (%)	CLL/SLL (n=19)	WM (n=21)	R/R MCL (n=12)	Total (N=55)
Any TEAE of special interest	16 (84.2)	17 (81.0)	10 (83.3)	44 (80.0)
Infections	13 (68.4)	11 (52.4)	5 (41.7)	30 (54.5)
Hemorrhage	8 (42.1)	11 (52.4)	5 (41.7)	25 (45.5)
Thrombocytopenia	3 (15.8)	4 (19.0)	3 (25.0)	11 (20.0)
Neutropenia	4 (21.1)	4 (19.0)	2 (16.7)	10 (18.2)
Anemia	4 (21.1)	2 (9.5)	0	6 (10.9)
Second primary malignancies	3 (15.8)	1 (4.8)	1 (8.3)	6 (10.9)
Hypertension	0	3 (14.3)	2 (16.7)	5 (9.1)
Atrial fibrillation and flutter	1 (5.3)	1 (4.8)	0	2 (3.6)

TLS was not reported in any patients

^a Median study follow-up time of 26.7 months (Data cutoff date: 10 May 2023)

CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma; R/R, relapsed or refractory;

TEAE, treatment-emergent adverse event; TLS, tumor lysis syndrome; WM, Waldenström macroglobulinemia.

1. Tam CS, et al. Lancet Oncol. 2022;23(8):1031-1043; 2. Brown JR. N Engl J Med. 2023;388(4):319-332;

3. Tam CS, et al. Blood. 2020;136(18):2038-2050; 4. Dimopoulos MA, et al. J Clin Oncol. 2023;JCO2202830.

Conclusions

- Zanubrutinib had high ORRs by IRC in Japanese patients in the ongoing BGB-3111-111 study
- The concordance rate between IRC-assessed and INV-assessed ORR was high
- Further follow-up (DCO 10 May 2023, N=55) did not show any new safety signals, and results were comparable to those from global studies
- High concordance rates between IRC and INV support the reliability of efficacy results of the BGB-3111-111 study and further supports zanubrutinib as an efficacious and safe BTKi for Japanese patients with CLL/SLL, WM, or R/R MCL

Acknowledgments

- The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers
- This study was sponsored by BeiGene, Ltd
- Medical writing support was provided by Brittany Gifford, PharmD, of Medical Expressions and was funded by BeiGene